Perioperative chemotherapy with docetaxel, cisplatin and capecitabine (DCX) in gastro-oesophageal adenocarcinoma: A phase II study of the Arbeitsgemeinschaft Internistische Onkologie (AIO)

Annals of Oncology

Volumn 23, Issue 11, 2012, Pages 2827-2834

  Thuss Patience, P C ^a   Hofheinz, R D ^b   Arnold, D ^c   Florschutz A ^d   Daum, S ^a   Kretzschmar, A ^e,f   Mantovani Loffler L ^f   Bichev, D ^a   Breithaupt, K ^a   Kneba, M ^g   Schumacher, G ^a,h   Glanemann, M ^a   Schlattmann, P ⁱ   Reichardt, P ^j   Gahn, B ^g  

^a CHARITÉ UNIVERSITÄTSMEDIZIN BERLIN   (Germany)

^b University Medicine Mannheim   (Germany)

^c UNIVERSITY MEDICAL CENTER HAMBURG EPPENDORF   (Germany)

^d DESSAU MEDICAL CENTER   (Germany)

^e HELIOS KLINIKUM BERLIN BUCH   (Germany)

^f Klinikum St Georg   (Germany)

^g UNIVERSITY HOSPITAL SCHLESWIG HOLSTEIN   (Germany)

^h KLINIKUM BRAUNSCHWEIG   (Germany)

ⁱ FRIEDRICH SCHILLER UNIVERSITY JENA   (Germany)

^j HELIOS Klinikum Bad Saarow   (Germany)

more..

Author keywords

Docetaxel; Gastro oesophageal adenocarcinoma; Neoadjuvant chemotherapy; pCR; R0 resection rate

Indexed keywords

CAPECITABINE; CISPLATIN; DOCETAXEL; GRANULOCYTE COLONY STIMULATING FACTOR;

ADULT; AGED; ALOPECIA; ANEMIA; ANOREXIA; ARTICLE; ASTHENIA; CANCER COMBINATION CHEMOTHERAPY; CANCER SURGERY; CATHETER INFECTION; CHEMOTHERAPY INDUCED EMESIS; DEHYDRATION; DIARRHEA; DIZZINESS; DRUG EFFICACY; DRUG HYPERSENSITIVITY; DRUG SAFETY; EDEMA; ESOPHAGEAL ADENOCARCINOMA; EVENT FREE SURVIVAL; FALLING; FEBRILE NEUTROPENIA; FEMALE; FEVER; GASTROESOPHAGEAL ADENOCARCINOMA; GASTROINTESTINAL HEMORRHAGE; HAND FOOT SYNDROME; HEAD INJURY; HEARING IMPAIRMENT; HUMAN; LEUKOPENIA; LOWER ESOPHAGUS SPHINCTER; LUNG EMBOLISM; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; MULTIPLE CYCLE TREATMENT; NAIL; NAUSEA; NEUROTOXICITY; NEUTROPENIA; OVERALL SURVIVAL; PANCREATITIS; PARESTHESIA; PERFORATION; PERIOPERATIVE CHEMOTHERAPY; PERIOPERATIVE PERIOD; PHASE 2 CLINICAL TRIAL; PRIORITY JOURNAL; PROSPECTIVE STUDY; SIDE EFFECT; STOMACH ADENOCARCINOMA; STOMATITIS; SURVIVAL RATE; TASTE; THROMBOCYTOPENIA; THROMBOSIS; TUMOR REGRESSION; VISUAL DISORDER;

ADENOCARCINOMA; ADULT; AGED; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CISPLATIN; DEOXYCYTIDINE; DRUG ADMINISTRATION SCHEDULE; ESOPHAGEAL NEOPLASMS; ESOPHAGOGASTRIC JUNCTION; FEMALE; FLUOROURACIL; HUMANS; MALE; MIDDLE AGED; PROSPECTIVE STUDIES; STOMACH NEOPLASMS; TAXOIDS; TREATMENT OUTCOME;

EID: 84868114897     PISSN: 09237534     EISSN: 15698041     Source Type: Journal    
DOI: 10.1093/annonc/mds129     Document Type: Article

References (35)

1. Kamangar F, Dores GM, Anderson WF. Patterns of cancer incidence, mortality, and prevalence across five continents: defining priorities to reduce cancer disparities in different geographic regions of the world. J Clin Oncol 2006; 24: 2137-2150.
2. Cunningham D, Allum WH, Stenning SP et al. Perioperative chemotherapy versus surgery alone for resectable gastroesophageal cancer. N Engl J Med 2006; 355: 11-20.
3. Ychou M, Boige V, Pignon JP et al. Perioperative chemotherapy compared with surgery alone for resectable gastroesophageal adenocarcinoma: A FNCLCC and FFCD multicenter phase III Trial. J Clin Oncol 2011; 29: 1715-1721.
4. Van Cutsem E, Van de Velde C, Roth A et al. Expert opinion on management of gastric and gastro-oesophageal junction adenocarcinoma on behalf of the European Organisation for Research and Treatment of Cancer (EORTC)-gastrointestinal cancer group. Eur J Cancer 2008; 44: 182-194.
5. Cunningham D, Starling N, Rao S et al. Capecitabine and oxaliplatin for advanced esophagogastric cancer. N Engl J Med 2008; 358: 36-46.
6. Bang YJ. Capecitabine in gastric cancer. Expert Rev Anticancer Ther 2011; 11 (12): 1791-1806.
7. Van Cutsem E, Moiseyenko VM, Tjulandin S et al. Phase III study of docetaxel and cisplatin plus fluorouracil compared with cisplatin and fluorouracil as first-line therapy for advanced gastric cancer: a report of the V325 Study Group. J Clin Oncol 2006; 24: 4991-4997.
8. Al-Batran SE, Hartmann JT, Hofheinz R et al. Biweekly fluorouracil, leucovorin, oxaliplatin, and docetaxel (FLOT) for patients with metastatic adenocarcinoma of the stomach or esophagogastric junction: a phase II trial of the Arbeitsgemeinschaft Internistische Onkologie. Ann Oncol 2008; 19(11): 1882-1887.
9. Lorenzen S, Hentrich M, Haberl C et al. Split-dose docetaxel, cisplatin and leucovorin/fluorouracil as first-line therapy in advanced gastric cancer and adenocarcinoma of the gastroesophageal junction: results of a phase II trial. Ann Oncol 2007; 18(10): 1673-1679.
10. Shah MA, Shibata S, Stoller RG et al. Random assignment multicenter phase II study of modified docetaxel, cisplatin, fluorouracil (mDCF) versus DCF with growth factor support (GCSF) in metastatic gastroesophageal adenocarcinoma (GE). J Clin Oncol 2010; 28: 15s (suppl.; abstract 4014).
11. Sym SJ, Chang HM, Ryu MH et al. Neoadjuvant docetaxel, capecitabine and cisplatin (DXP) in patients with unresectable locally advanced or metastatic gastric cancer. Ann Surg Oncol 2010; 17: 1024-1032.
12. Sobin LH, Wittekind Ch (eds). TNM Classification of Malignant Tumours, 6th edition. Hoboken, NJ: John Wiley & Sons 2002.
13. Therasse P, Arbuck SG, Eisenhauer EA et al. New guidelines to evaluate the response to treatment in solid tumors. J Natl Cancer Inst 2000; 92(3): 205-216.
14. Becker K, Mueller JD, Schulmacher C et al. Histomorphology and grading of regression in gastric carcinoma treated with neoadjuvant chemotherapy. Cancer 2003; 98(7): 1521-1530.
15. Simon R. Optimal two-stage designs for phase II clinical trials. Control Clin Trials 1989; 10: 1-10.
16. Ott K, Sendler A, Becker K et al. Neoadjuvant chemotherapy with cisplatin, 5-FU, and leucovorin (PLF) in locally advanced gastric cancer: a prospective phase II study. Gastric Cancer 2003; 6(3): 159-167.
17. Brenner B, Shah MA, Karpeh MS et al. A phase II trial of neoadjuvant cisplatinfluorouracil followed by postoperative intraperitoneal floxuridine-leucovorin in patients with locally advanced gastric cancer. Ann Oncol 2006; 17(9): 1404-1411.
18. Agresti A, Coull BA. Approximate is better than 'exact' for interval estimation of binomial proportions. Am Stat 1998; 52(2): 119-126.
19. Sundar D-R. binom: Binomial Confidence Intervals For Several Parameterizations. R package version 1.0-5. 2009; http://CRAN.R-project.org/package=binom (16 January 2012, date last accessed).
20. Lorenzen S, Duyster J, Lersch C et al. Capecitabine plus docetaxel every 3 weeks in first-and second-line metastatic oesophageal cancer: final results of a phase II trial. Br J Cancer 2005; 92: 2129-2133.
21. Giordano KF, Jatoi A, Stella PJ et al. Docetaxel and capecitabine in patients with metastatic adenocarcinoma of the stomach and gastroesophageal junction: a phase II study from the North Central Cancer Treatment Group. Ann Oncol 2006; 17: 652-656.
22. Thuss-Patience PC, Kretzschmar A, Dogan Y et al. Docetaxel and capecitabine for advanced gastric cancer: investigating dose-dependent efficacy in two patient cohorts. Br J Cancer 2011; 105: 505-512.
23. Biffi R, Fazio N, Luca F et al. Surgical outcome after docetaxel-based neoadjuvant chemotherapy in locally-advanced gastric cancer. World J Gastroenterol 2010; 16: 868-874.
24. Claxton AJ, Cramer J, Pierce C. A systematic review of the associations between dose regimens and medication compliance. Clin Ther 2001; 23: 1296-1310.
25. Chun JH, Kim HK, Lee JS et al. Weekly docetaxel in combination with capecitabine in patients with metastatic gastric cancer. Am J Clin Oncol 2005; 28: 188-194.
26. Park YH, Ryoo BY, Choi SJ, Kim HT. A phase II study of capecitabine and docetaxel combination chemotherapy in patients with advanced gastric cancer. Br J Cancer 2004; 90: 1329-1333.
27. Kim JG, Sohn SK, Kim DH et al. Phase II study of docetaxel and capecitabine in patients with metastatic or recurrent gastric cancer. Oncology 2005; 68: 190-195.
28. Starling N, Okines A, Cunningham D et al. A phase II trial of preoperative chemotherapy with epirubicin, cisplatin and capecitabine for patients with localised gastro-oesophageal junctional adenocarcinoma. Br J Cancer 2009; 100: 1725-1730.
29. Homann N, Pauligk C, Luley K et al. Pathological complete remission in patients with oesophagogastric cancer receiving preoperative 5-fluorouracil, oxaliplatin and docetaxel. Int J Cancer 2012; 130: 1706-1713.
30. Burmeister BH, Smithers BM, Gebski V et al. Surgery alone versus chemoradiotherapy followed by surgery for resectable cancer of the oesophagus: a randomised controlled phase III trial. Lancet Oncol 2005; 6(9): 659-668.
31. Stahl M, Walz MK, Stuschke M et al. Phase III comparison of preoperative chemotherapy compared with chemoradiotherapy in patients with locally advanced adenocarcinoma of the esophagogastric junction. J Clin Oncol 2009; 27(6): 851-856.
32. Tepper J, Krasna MJ, Niedzwiecki D et al. Phase III trial of trimodality therapy with cisplatin, fluorouracil, radiotherapy, and surgery compared with surgery alone for esophageal cancer: CALGB 9781. J Clin Oncol 2008; 26(7): 1086-1092.
33. Sjoquist KM, Burmeister BH, Smithers BM et al. Survival after neoadjuvant chemotherapy or chemoradiotherapy for resectable oesophageal carcinoma: an updated meta-analysis. Lancet Oncol 2011; 12(7): 681-692 [epub ahead of print 16 June 2011].
34. Fareed KR, Al-Attar A, Soomro IN et al. Tumour regression and ERCC1 nuclear protein expression predict clinical outcome in patients with gastro-oesophageal cancer treated with neoadjuvant chemotherapy. Br J Cancer 2010; 102 (11): 1600-1607.
35. Ferri LE, Ades S, Alcindor T et al. Perioperative docetaxel, cisplatin, and 5-fluorouracil (DCF) for locally advanced esophageal and gastric adenocarcinoma: Safety and response results from a multicenter phase II trial. J Clin Oncol 2010; 28: 15s (suppl.; abstract 4075).